Praxis Precision Medicines, Inc.

XNASHealth care

Last traded price · USD

$284.79

+1.53%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: $286.87
Previous close: $280.51
Volume: 372,764
Day's high: $287.60
Day's low: $274.23

In brief

Praxis Precision Medicines, Inc. is a health care company listed on Nasdaq, valued at about $7.95B.
Its shares closed at $284.79 on 4 Nov 2026, up 65.8% over the past year.
From India you can buy PRAX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Praxis Precision Medicines, Inc. (PRAX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PRAX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PRAX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +1.7% (SPY −1.6%, XLV +13.5%). 3 months: −10.8% (SPY −0.4%, XLV +15.5%). 1 year: +65.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PRAX, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $284.79 was 3.7% below its 50-day average ($295.83) and 9.4% below its 200-day average ($314.34). It has closed below the 200-day for 36 sessions, since 16 Sep 2026. The 50-day average crossed below the 200-day on 22 Oct 2026, 9 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
7.4 days to cover short interest
3.9M shares were sold short at the 15 Oct 2026 settlement, 14.0% of the 27.9M shares outstanding; covering them would take 7.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
54% of the way up its 52-week range
Closed at $284.79 on 4 Nov 2026: 27.5% below the 52-week high of $392.70 (20 Aug 2026) and 78.3% above the low of $159.74 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.7%

6 months−15.8%

1 year+65.8%

5 years−14.6%

Newswire

About

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Website

Notable moves

October 16, 2025
+183.71%
March 3, 2023
−65.87%
June 6, 2022
−78.11%

Newswire

About

Website

Notable moves

October 16, 2025
+183.71%
March 3, 2023
−65.87%
June 6, 2022
−78.11%

Praxis Precision Medicines, Inc.

XNASHealth care

Last traded price · USD

$284.79

+1.53%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: $286.87
Previous close: $280.51
Volume: 372,764
Day's high: $287.60
Day's low: $274.23

In brief

Praxis Precision Medicines, Inc. is a health care company listed on Nasdaq, valued at about $7.95B.
Its shares closed at $284.79 on 4 Nov 2026, up 65.8% over the past year.
From India you can buy PRAX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Praxis Precision Medicines, Inc. (PRAX) shares from India?

Do I need the price of a whole PRAX share to invest?

How much can I invest in US stocks in a year?

Can I trade PRAX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +1.7% (SPY −1.6%, XLV +13.5%). 3 months: −10.8% (SPY −0.4%, XLV +15.5%). 1 year: +65.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PRAX, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $284.79 was 3.7% below its 50-day average ($295.83) and 9.4% below its 200-day average ($314.34). It has closed below the 200-day for 36 sessions, since 16 Sep 2026. The 50-day average crossed below the 200-day on 22 Oct 2026, 9 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
7.4 days to cover short interest
3.9M shares were sold short at the 15 Oct 2026 settlement, 14.0% of the 27.9M shares outstanding; covering them would take 7.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
54% of the way up its 52-week range
Closed at $284.79 on 4 Nov 2026: 27.5% below the 52-week high of $392.70 (20 Aug 2026) and 78.3% above the low of $159.74 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.7%

6 months−15.8%

1 year+65.8%

5 years−14.6%

Newswire

About

Website

Notable moves

October 16, 2025
+183.71%
March 3, 2023
−65.87%
June 6, 2022
−78.11%

Newswire

About

Website

Notable moves

October 16, 2025
+183.71%
March 3, 2023
−65.87%
June 6, 2022
−78.11%

Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

7.4 days to cover short interest

54% of the way up its 52-week range

Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

7.4 days to cover short interest

54% of the way up its 52-week range